ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Jaume Pons sold 20,000 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $11.15, for a total value of $223,000.00. Following the sale, the insider now owns 628,359 shares of the company's stock, valued at $7,006,202.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
ALX Oncology Trading Up 8.8 %
NASDAQ ALXO opened at $12.23 on Friday. ALX Oncology Holdings Inc. has a fifty-two week low of $3.94 and a fifty-two week high of $17.42. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24. The stock has a 50 day simple moving average of $13.78 and a two-hundred day simple moving average of $11.36. The stock has a market cap of $613.33 million, a P/E ratio of -3.26 and a beta of 1.58.
ALX Oncology (NASDAQ:ALXO - Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, analysts forecast that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current year.
Institutional Inflows and Outflows
The biggest energy story ever?
From Porter & Company | Ad
Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…
For the full story, click here.
Institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of ALX Oncology in the 4th quarter worth approximately $28,000. Royal Bank of Canada raised its position in shares of ALX Oncology by 226.6% in the 2nd quarter. Royal Bank of Canada now owns 4,001 shares of the company's stock worth $30,000 after acquiring an additional 2,776 shares in the last quarter. Legal & General Group Plc raised its position in shares of ALX Oncology by 42.6% in the 4th quarter. Legal & General Group Plc now owns 2,289 shares of the company's stock worth $34,000 after acquiring an additional 684 shares in the last quarter. UBS Group AG raised its position in shares of ALX Oncology by 38.7% in the 1st quarter. UBS Group AG now owns 10,043 shares of the company's stock worth $45,000 after acquiring an additional 2,801 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of ALX Oncology in the 3rd quarter worth approximately $48,000. Institutional investors own 97.97% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. Stifel Nicolaus restated a "hold" rating and set a $14.00 target price (up from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. Jefferies Financial Group upgraded ALX Oncology from a "hold" rating to a "buy" rating and increased their price objective for the stock from $8.00 to $18.00 in a report on Friday, December 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $18.42.
View Our Latest Report on ALX Oncology
About ALX Oncology
(
Get Free Report)
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
